Zentalis Pharmaceuticals(NASDAQ) ZNTL

Zentalis Pharmaceuticals, Inc. makes new cancer medicines. These drugs help patients by stopping tumor growth. The company focuses on treating ovarian cancer.

Key Drug Candidates and Tools

• Azenosertib (ZN-c3): Investigational oral medicine designed to block the WEE1 protein to prevent cancer cells from repairing themselves.
• Companion Diagnostic: Protein-based test developed with a partner to identify patients most likely to benefit from treatment.
• Combination Therapies: Clinical programs pairing azenosertib with standard chemotherapies like paclitaxel to improve patient outcomes.

Progress Toward Regulatory Approval

• Dosed the first patient in the Phase 3 ASPENOVA clinical trial in May 2026.
• Met with the FDA in July 2026 to align on regulatory strategies for an accelerated approval pathway.
• Announced the selection of the pivotal monotherapy dose for its primary clinical program in April 2026.
• Reorganized the company in January 2025 to focus resources on late-stage clinical development.

Unique Focus on Biomarkers

Zentalis uses specific biological markers to identify patients most likely to respond to its oncology treatments. It maintains global control of its lead product candidates through sole ownership or exclusive worldwide licenses.

Measuring the Financial Health

• Cash, cash equivalents, and marketable securities reached $174.6 million as of June 30, 2026.
• Net loss was $77.6 million for the six months ended June 30, 2026.
• Research and development expenses were $35.2 million for the three months ended June 30, 2026, up $7.6 million year over year.
• Accumulated deficit reached $1.3 billion as of June 30, 2026.
• Held $69.5 million available for sale under an at-the-market stock offering program as of June 30, 2026.

Business Evolution

Zentalis has transitioned from drug discovery to focusing on late-stage clinical trials for its lead oncology candidate. It streamlined operations in early 2025 to prioritize azenosertib and extend its financial runway into late 2027.